- 1. B Cell
- [lymphoid cells concerned with humoral immunity; they are short lived cells resembling bursa derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. ( CSP )] (UMLS (NCI) C0004561) =Cell ;
| - 22. B-Cell CLL/Lymphoma 6 (Zinc Finger Protein 51) Gene
- [This gene is involved in transcriptional repression and plays a role in the modulation of B-cell responses. ( NCI )] (UMLS (NCI) C1332399) B-Cell CLL/Lymphoma-6 Gene;
BCL5;
BCL6;
BCL6 Gene;
Cys-His2 Zinc Finger Transcription Factor Gene;
LAZ3;
LAZ-3 Gene;
Lymphoma-Associated Zinc Finger Gene on Chromosome 3;
Zinc Finger Protein 51 Gene;
ZNF51;
ZNF51 Gene =Gene or Genome ;
|
- 2. B Cell Childhood Acute Lymphoblastic Leukemia
- (UMLS (NCI) C0279584) =Neoplastic Process
| - 23. B-Cell CLL/Lymphoma 7A Gene
- (UMLS (NCI) C1332400) BCL7A;
BCL7A Gene;
=Gene or Genome ;
|
- 3. B Cell Chronic Lymphocytic Leukemia
- [A slowly progressing disease in which too many white blood cells (called lymphocytes) are found in the body. ( NCI )] (UMLS (NCI) C0023434) =Neoplastic Process ;
=Leukemia, Lymphocytic;
=Acute B Cell Lymphocytic Leukemia;
Leukemia, B-Cell, Chronic;
Leukemia, Pre-B-Cell;
| - 24. B-Cell CLL/Lymphoma 9 Gene
- [This gene plays a role in signal transduction and is involved in development. ( NCI )] (UMLS (NCI) C1332402) BCL9;
BCL9 Gene;
=Gene or Genome ;
|
- 4. B Cell Differentiation Factor I
- [lymphokine produced by antigen or mitogen activated T lymphocytes that acts as a differentiation factor for B lymphocytes and eosinophils and increases the production of IgA by B lymphocytes. ( CSP )] (UMLS (NCI) C0021759) =Amino Acid, Peptide, or Protein; Immunologic Factor =lymphokine;
hematopoietic growth factor | - 25. B-cell CLL/Lymphoma-6
- [B-Cell Lymphoma 6 Protein is a zinc finger transcription factor containing an N-terminal POZ domain. It acts as a sequence-specific repressor of transcription and its activity is dependent upon DNA-binding and on the N-terminal region containing the POZ motif. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. Target genes have roles in B-cell activation, B-cell differentiation, inflammation, and cell cycle control. Expression of BCL6 in some B-cells early in the antigen response may skew them toward a germinal center fate, away from a plasma cell fate. The BCL6 gene is found to be frequently translocated and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in the pathogenesis of DLCL. (from OMIM, LocusLink and NCI) ( NCI )] (UMLS (NCI) C0248007) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
|
- 5. B Cell Linker Protein
- [B-Cell Linker, encoded by the BLNK gene, is essential for normal B-cell development. This protein interfaces the B-cell receptor-associated SYK tyrosine kinase with PLC-gamma, the VAV guanine nucleotide exchange factor, and the GRB2 and NCK adaptor proteins. Tyrosine phosphorylation of B-Cell Linker by SYK provides docking sites for these SH2-containing effector molecules that, in turn permits the phosphorylation and/or activation of their respective signaling pathways. Thus, B-Cell Linker represents a central linker protein that bridges the B-cell receptor-associated kinases with a multitude of signaling pathways and may regulate biologic outcomes of B-cell function and development. The somatic loss of the BLNK gene and the accompanying block in pre-B-cell differentiation might be one of the primary causes of childhood pre-B ALL. (From OMIM and NCI) ( NCI )] (UMLS (NCI) C0756331) B-Cell Linker;
B-Cell Linker Protein;
BLNK;
=Amino Acid, Peptide, or Protein; Immunologic Factor | - 26. B-Cell Deficiency
- (UMLS (NCI) C0522274) =Disease or Syndrome
|
- 6. B Cell Lymphoma Stage II
- [Stage II NHL means involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (PDQ) ( NCI )] (UMLS (NCI) C0855092) B-Cell Lymphoma Stage II;
Stage II B Cell Lymphoma;
Stage II B-Cell Lymphoma;
Stage II B-Cell Non-Hodgkin Lymphoma;
Stage II B-Cell Non-Hodgkin's Lymphoma =Neoplastic Process | - 27. B-Cell Diffuse Large Cell Lymphoma of Mediastinum
- [A large B-cell non-Hodgkin lymphoma arising in the mediastinum. Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis. Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001) ( NCI )] (UMLS (NCI) C0855152) B-Cell Diffuse Large Cell Lymphoma of the Mediastinum;
Mediastinal (Thymic) Large B-Cell Lymphoma;
Mediastinal B-Cell Diffuse Large Cell Lymphoma;
Primary Mediastinal Large B-Cell Lymphoma =Neoplastic Process |
- 7. B Cell Lymphoma Stage III
- [Stage III NHL means involvement of lymph node regions on both sides of the diaphragm (III) that may also be accompanied by localized involvement of an extralymphatic organ or site (IIIE), by involvement of the spleen (IIIS), or both (IIIS+E). (PDQ) ( NCI )] (UMLS (NCI) C0855093) B-Cell Lymphoma Stage III;
Stage III B Cell Lymphoma;
Stage III B-Cell Lymphoma;
Stage III B-Cell Non-Hodgkin Lymphoma;
Stage III B-Cell Non-Hodgkin's Lymphoma =Neoplastic Process | - 28. B-Cell Lineage Specific Activator Protein
- [Paired Box 5, encoded by the PAX5 gene, is a member of the paired box (PAX) family of transcription factors. Paired Box 5 is expressed at early stages of B-cell differentiation. Its expression is also detected in developing CNS and testis. Paired Box 5 may not only play an important role in B-cell differentiation, but also in neural development and spermatogenesis. This gene is located in chromosome 9p13 region, which is involved in t(9;14)(p13;q32) translocations recurring in small lymphocytic lymphomas of the plasmacytoid subtype, and in derived large-cell lymphomas. This translocation brings the potent E-mu enhancer of the IgH gene into close proximity of the PAX5 promoters. Deregulation of PAX5 gene transcription may contribute to the pathogenesis of these lymphomas. (from LocusLink) ( NCI )] (UMLS (NCI) C0167636) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
|
- 8. B Cell Lymphoma Stage IV
- [Stage IV NHL means disseminated (multifocal) involvement of one or more extralymphatic sites with or without associated lymph node involvement or isolated extralymphatic organ involvement with distant (nonregional) nodal involvement. (PDQ) ( NCI )] (UMLS (NCI) C0855094) B-Cell Lymphoma Stage IV;
Stage IV B Cell Lymphoma;
Stage IV B-Cell Lymphoma;
Stage IV B-Cell Non-Hodgkin Lymphoma;
Stage IV B-Cell Non-Hodgkin's Lymphoma =Neoplastic Process | - 29. B-Cell Linker Gene
- [This gene plays a role in signal transduction and B-cell development. ( NCI )] (UMLS (NCI) C1332420) BLNK;
BLNK Gene;
=Gene or Genome |
- 9. B Cell Proliferation
- [Growth and reproduction of B-lymphocytes. ( NCI )] (UMLS (NCI) C1155008) =Cell Function
| - 30. B-Cell Lymphocytic Neoplasm
- (UMLS (NCI) C1332362) B-Cell Neoplasm;
=Neoplastic Process ;
|
- 10. B Cell-Associated Molecule CD40
- [50 kD glycoprotein expressed on all B cells; plays an important role in B cell development and activation. ( CSP )] (UMLS (NCI) C0054959) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor =CD antigen;
| - 31. B-Cell Lymphoma Recurrent
- [The reemergence of B-cell non-Hodgkin lymphoma after a period of remission ( NCI )] (UMLS (NCI) C0855089) Recurrent B-Cell Lymphoma;
Recurrent B-Cell Non-Hodgkin Lymphoma;
Recurrent B-Cell Non-Hodgkin's Lymphoma =Neoplastic Process |
- 11. B-Cell Activation
- [A set of events occurring in B lymphocytes following stimulation with cognate antigen. Crosslinking the B cell antigen receptor (surface immunoglobulin) leads to increased expression of MHC class II molecules, exit from the resting state (G0) into the G1 phase of the cell cycle, and in the case of a strong antigenic stimulus, proliferation. ( NCI )] (UMLS (NCI) C1155003) =Cell Function
| - 32. B-Cell Lymphoma Refractory
- [B-cell non-Hodgkin lymphoma that is resistant to treatment ( NCI )] (UMLS (NCI) C0855090) Refractory B-Cell Lymphoma;
Refractory B-Cell Non-Hodgkin Lymphoma;
Refractory B-Cell Non-Hodgkin's Lymphoma =Neoplastic Process |
- 12. B-Cell Activation Protein BL34
- [Induced in response to several activation signals and encoded by B-cell specific immediate early human RGS1 Gene (RGS Family), 196-aa 22.5-kDa Regulator of G-Protein Signaling 1, containing 1 RGS domain, is likely involved in regulation of B-cell activation and proliferation. Potentially regulated by protein kinase(s), RGS1 inhibits signal transduction by increasing GTPase activity of G protein alpha subunits, driving them into the inactive GDP-bound form. ( NCI )] (UMLS (NCI) C1448758) Early Response Protein 1R20;
Regulator of G-Protein Signaling 1;
RGS1;
=Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 33. B-Cell Proliferation of Uncertain Malignant Potential
- (UMLS (NCI) C1332363) =Neoplastic Process ;
|
- 13. B-Cell Chronic Lymphocytic Leukemia Tumor Suppressor LEU5
- [Encoded by human RFP2 Gene (TRIM Family), 407-aa 47-kDa RET Finger Protein 2, of unknown function, is localized to cytoplasmic bodies near the nucleus and contains a TRIM motif: 3 zinc-binding domains, a RING, type 1 and type 2 B-boxes, and a coiled-coil region. RFP2 may act as a tumor suppressor and may be involved in 13q14 deletion B-CLL. (NCI) ( NCI )] (UMLS (NCI) C1308524) CLL-Associated RING Finger;
Leukemia Associated Protein 5;
Putative Tumor Suppressor RFP2;
RET Finger Protein 2;
Tripartite Motif Protein 13 =Amino Acid, Peptide, or Protein; Biologically Active Substance | - 34. B-Cell Small Lymphocytic Lymphoma
- [A non-Hodgkin lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes. When the lymphoid process involves predominantly the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001) ( NCI )] (UMLS (NCI) C0855095) Diffuse Well Differentiated Lymphocytic Lymphoma;
Lymphoma, Small Lymphocytic;
SLL;
Small B-Cell Lymphocytic Lymphoma;
Small Lymphocytic Lymphoma =Neoplastic Process =Lymphoma, Small-Cell;
Lymphoma, Diffuse;
Low Grade Lymphoma;
|
- 14. B-Cell CLL Protein
- [Expressed in thymus, prostate, testis, ovary, small intestine, spleen, colon, and blood, 85-kb human BCL9 Gene at 1q21 encodes 1426-aa 150-kD nuclear B-Cell Lymphoma 9 Protein, containing an HD1 domain that interacts with the conserved PHD finger of PYGO1 and PYGO2. BCL9 (Lgs homolog, Drosophila) also binds to beta-Catenin, involved in WNT signal transduction pathway control of many fundamental developmental processes. BCL9 recruitment of PYGO to beta-Catenin may permit association with DNA-binding TCF to transcriptionally activate WNT target genes. BCL9 translocation that leaves the coding region intact is associated with B-cell acute lymphoblastic leukemia. ( NCI )] (UMLS (NCI) C0672585) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 35. B-Cell Small Lymphocytic Lymphoma Refractory
- [B-cell small lymphocytic lymphoma that is resistant to treatment ( NCI )] (UMLS (NCI) C0855097) Refractory B-Cell Small Lymphocytic Lymphoma;
Refractory Small Lymphocytic Lymphoma;
=Neoplastic Process |
- 15. B-Cell CLL Protein
- [Encoded by widely expressed human BCL7A Gene, 231-aa 25-kD serine-rich BCL7A Protein has 90% sequence identity (N-terminal 51-aa) with BCL7B and BCL7C; possible members of an evolutionarily conserved family. BCL7A exhibits no recognizable motifs but shows homology with actin-binding Caldesmon. Recurrent three-way translocations of BCL7A with MYC and IGH occur in a high-grade B cell non-Hodgkin (Burkitt) lymphoma; the N-terminal BCL7A region is disrupted. ( NCI )] (UMLS (NCI) C1307696) BCL7A;
BCL7A Protein;
Lymphoma 7A Protein;
=Amino Acid, Peptide, or Protein; Biologically Active Substance | - 36. B-Cell Small Lymphocytic Lymphoma Stage I
- [Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).- 2003 ( NCI )] (UMLS (NCI) C0855098) Small Lymphocytic Lymphoma Stage I;
Stage I B-Cell Small Lymphocytic Lymphoma;
Stage I Small Lymphocytic Lymphoma =Neoplastic Process |
- 16. B-Cell CLL/Lymphoma 10
- [The gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. (LocusLink) ( NCI )] (UMLS (NCI) C0766164) BCL10;
CARD-Containing Proapoptotic Protein;
CARD-Like Apoptotic Protein;
Caspase-Recruiting Domain-Containing Protein;
=Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 37. B-Cell Small Lymphocytic Lymphoma Stage II
- [Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE). - 2003 ( NCI )] (UMLS (NCI) C0855099) Small Lymphocytic Lymphoma Stage II;
Stage II B-Cell Small Lymphocytic Lymphoma;
Stage II Small Lymphocytic Lymphoma =Neoplastic Process |
- 17. B-Cell CLL/Lymphoma 10 Gene
- [This gene is involved in the promotion of apoptosis. ( NCI )] (UMLS (NCI) C1367449) BCL10;
BCL10 Gene =Gene or Genome | - 38. B-Cell Small Lymphocytic Lymphoma Stage III
- [Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S). - 2003 ( NCI )] (UMLS (NCI) C0855100) Small Lymphocytic Lymphoma Stage III;
Stage III B-Cell Small Lymphocytic Lymphoma;
Stage III Small Lymphocytic Lymphoma =Neoplastic Process |
- 18. B-Cell CLL/lymphoma 2
- [A mitochondrial membrane protein, BCL-2 protein is responsible for blocking apoptosis in normal cells. Growth factor-stimulated phosphorylation by PKC promotes anti-apoptotic activity of BCL-2 during G2/M. BCL-2 regulates cell death by controlling mitochondrial membrane permeability. Cleavage by caspases during apoptosis yields a pro-apoptotic BCL-2 product that causes release of cytochrome C into the cytosol, promoting further caspase activity. Over expression from translocation t(14;18) of BCL-2 with the immunoglobulin gene region is involved in B-cell lymphomas. (from OMIM 151430 and NCI) ( NCI )] (UMLS (NCI) C0597712) =Amino Acid, Peptide, or Protein; Biologically Active Substance
| - 39. B-Cell Small Lymphocytic Lymphoma Stage IV
- [Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow or nodular involvement of the lung(s). - 2003 ( NCI )] (UMLS (NCI) C0855101) Metastatic Small Lymphocytic Lymphoma;
Small Lymphocytic Lymphoma Stage IV;
Stage IV B-Cell Small Lymphocytic Lymphoma;
Stage IV Small Lymphocytic Lymphoma;
=Neoplastic Process |
- 19. B-Cell CLL/Lymphoma 2 Gene
- [This gene is involved in apoptotic regulation. Overexpression of this gene promotes the pathogenesis of B-Cell lymphomas, due to anti-apoptotic activity. ( NCI )] (UMLS (NCI) C0376515) =Gene or Genome
| - 40. B-Cell Translocation Gene 2 Protein
- [This protein is a member of the BTG/Tob family. This family has structurally related proteins that appear to have antiproliferative properties. This protein is involved in the regulation of the G1/S transition of the cell cycle. (LocusLink) ( NCI )] (UMLS (NCI) C1505113) BTG Family, Member 2;
BTG2;
BTG2 Protein;
NGF-Inducible Anti-Proliferative Protein PC3 =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
|
- 20. B-Cell CLL/Lymphoma 3
- [A possible transcriptional activating factor, BCL3 is activated by phosphorylation and functions as an IKB specific for the p50 subunit of NFKB, inhibiting its translocation to the nucleus. BCL3 confers a survival advantage to T-cells, possibly by promoting the expression of genes repressed by NFKB members. Translocation t(14;19)(q32;q13.1), involving BCL3 and immunoglobulin gene regions, is associated with B-CLL. (from OMIM 109560 and NCI) ( NCI )] (UMLS (NCI) C0640485) =Amino Acid, Peptide, or Protein; Biologically Active Substance
| - 41. B-cell/myeloid kinase
- [May serve as part of a signaling pathway coupling the FC receptor to the activation of the respiratory burst. Furthermore, it may also contribute to neutrophil migration and may regulate the degranulation process of neutrophils. p60-HCK and p59-HCK are produced by alternative initiation from the same proto-oncongene HCK. Both are expressed predominantly in cells of the myeloid and b-lymphoid lineages, thus also called B-cell/Myeloid kinase. Contains 1 sh2 domain and 1 sh3 domain. Has been mapped to chromosomal location 20q11-q12. ( NCI )] (UMLS (NCI) C0919495) Hemopoietic Cell Kinase p60;
p60-HCK;
=Amino Acid, Peptide, or Protein; Enzyme |
- 21. B-Cell CLL/Lymphoma 3 Gene
- [This gene is involved in transcriptional co-activation and signal transduction. ( NCI )] (UMLS (NCI) C0812238) BCL3;
BCL3 Gene =Gene or Genome | - 42. B-CEPP
- (UMLS (NCI) C0279240) =Therapeutic or Preventive Procedure ;
|
home
